Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHA:603896)

Market Cap	2.77B -34.3%
Revenue (ttm)	625.30M -5.3%
Net Income	-11.56M
EPS	-0.06
Shares Out	198.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	0.27 (1.91%)
Ex-Dividend Date	Jun 6, 2025

Volume	3,125,258
Open	13.93
Previous Close	13.99
Day's Range	13.88 - 14.38
52-Week Range	13.75 - 23.04
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHA:603896

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. engages in the selection, cultivation, processing, and sale of medicinal materials in China. It offers Ganoderma lucidum spore powder and brand broken cell wall powder, as well as broken wall Ganoderma lucidum spore powder granules and powder tablets; Tiepi Fengdou granules; and Tiepi Fengdou Ganoderma lucidum extracts. The company offers its products under the Shouxiangu brand. Zhejiang Shouxiangu Pharmaceutical Co., Ltd. was founded in 1997 and is headquartered in Jinhua, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 1,119
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603896

Financial Performance

In 2025, SHA:603896's revenue was 640.18 million, a decrease of -9.21% compared to the previous year's 705.11 million. Earnings were 18.17 million, a decrease of -89.58%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 23, 2026

Data Sources Report a data error